Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 18/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4998442 | 0.94 | LTA4H (0.51) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL4998706 | 0.90 | LTA4H (0.49) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL5004219 | 0.90 | LTA4H (0.47) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL4996054 | 0.89 | SMN1; SMN2 (0.47) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL4998109 | 0.89 | LTA4H (0.51) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL4998072 | 0.88 | LTA4H (0.47) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL4994303 | 0.86 | LTA4H (0.44) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL4998726 | 0.86 | LTA4H (0.45) | LTA4HKCNH2EPHX2PPARGPPARA | |
| SCHEMBL4998617 | 0.84 | LTA4H (0.44) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL4996090 | 0.84 | LTA4H (0.44) | LTA4HKCNH2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194630-A1 | Leukotriene A-4 hydrolase inhibitors; antiinflammatory agents; skin disorders; analgesics; stroke; anticancer agents; antiallergens; rhinitis;cystic fibrosis;sepsis | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194630-A1 | Leukotriene A-4 hydrolase inhibitors; antiinflammatory agents; skin disorders; analgesics; stroke; anticancer agents; antiallergens; rhinitis;cystic fibrosis;sepsis | LTA4H, LTC4S, LTB4R | LTA4H 1/4885KCNH2 2161/4885EPHX2 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.